These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23568765)

  • 1. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
    Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
    Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
    Blazer M; Phillips G; Reardon J; Efries D; Smith Y; Weatherby L; Juergens K; Rose J; Griffith N; Bekaii-Saab T
    Oncology; 2012; 83(3):135-40. PubMed ID: 22814309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
    Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
    BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
    Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
    Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
    Chan A; Low XH; Yap KY
    J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
    Chan A; Tan SH; Low XH; Yap KY
    Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
    Takemoto H; Nishimura J; Komori T; Kim HM; Ota H; Suzuki R; Ikenaga M; Ikeda M; Yamamoto H; Satoh T; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M;
    Int J Clin Oncol; 2017 Feb; 22(1):88-95. PubMed ID: 27465476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
    Al-Salloum HF; Al-Harbi HE; Abdelazeem A
    J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
    Navari RM; Ruddy KJ; LeBlanc TW; Nipp R; Clark-Snow R; Schwartzberg L; Binder G; Bailey WL; Potluri R; Schmerold LM; Papademetriou E; Roeland EJ
    Oncologist; 2021 Apr; 26(4):325-331. PubMed ID: 33289268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
    Hesketh PJ; Bosnjak SM; Nikolic V; Rapoport B
    Support Care Cancer; 2011 Dec; 19(12):2063-6. PubMed ID: 21976035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
    Hesketh PJ; Sanz-Altamira P; Bushey J; Hesketh AM
    Support Care Cancer; 2012 May; 20(5):1043-7. PubMed ID: 21553313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
    Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
    Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
    Koopman M; Antonini NF; Douma J; Wals J; Honkoop AH; Erdkamp FL; de Jong RS; Rodenburg CJ; Vreugdenhil G; Akkermans-Vogelaar JM; Punt CJ
    Ann Oncol; 2006 Oct; 17(10):1523-8. PubMed ID: 16873425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
    Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
    Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
    Sato Y; Hayakawa Y; Tatematsu M; Muro K; Noma H; Okamoto H
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1215-9. PubMed ID: 22902445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.